Search clinical trials for: bortezomib

Total 981 results

PETHEMA Foundation

Recruiting

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Refractory Multiple Myeloma

Spain
Federal Research Institute of Pediatric Hematology...

Recruiting

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) (ALL-MB 2015)

Childhood Acute Lymphoblastic Leukemia

Armenia, Belarus, Kyrgyzstan, Russian Federation, Uzbekistan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recurrent Adult Lymphoblastic Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

Neoplasms | Myelodysplastic Syndromes | Lymphomas

United States
Karyopharm Therapeutics Inc
Bristol-Myers Squibb

Active, not recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

Multiple Myeloma

United States, Canada
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

Multiple Myeloma

United States
Celgene

Active, not recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Multiple Myeloma

United States, Canada, Italy, Czechia, Denmark, France, Germany, Greece, Spain
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Natural Killer Cells and Bortezomib to Treat Cancer

Multiple Myeloma | Chronic Myeloid Leukemia (CML) | Pancreatic Ca | Colon/Rectal Ca | Carcinoma, Non-Small -Cell Lung

United States
National Cancer Institute (NCI)

Suspended

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV

HIV | Hematologic Malignancies

United States
Takeda

Active, not recruiting

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Multiple Myeloma

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more
Indiana University

Withdrawn

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia, Adult | Bone Marrow Transplant Complications

United States
Peking Union Medical College Hospital

Completed

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia (RRAIHA01)

Autoimmune Hemolytic Anemia | Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia

China
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Amyloidosis

United States, Netherlands, Belgium, Korea, Republic of, France, Sweden, Israel, Turkey, United Kingdom, Brazil, Canada, Mexico, Australia, Germany, Japan, Spain, Denmark, Italy, China, Greece, Poland, Hungary
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Multiple Myeloma

Canada, United States, Israel, Czechia, Turkey, Germany, United Kingdom, Japan, Netherlands, France, Brazil, Poland, Spain
Janssen Research & Development, LLC

Completed

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Multiple Myeloma

Korea, Republic of, Malaysia, China, Taiwan, Hong Kong
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Philippines, United Kingdom
Giselle Sholler
Beat NB Cancer Foundation; Because of Ezra; K C Pharmaceuticals Inc.

Completed

Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

Neuroblastoma Recurrent

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2)

Multiple Myeloma

United States, Belgium, United Kingdom, France, Australia
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (VEGA)

Lymphoma, Mantle-Cell

Taiwan, Thailand, Malaysia, India, Puerto Rico, Spain, Turkey, Czechia, Brazil, Greece, Poland, Sweden, Romania
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)

Multiple Myeloma

United States, Netherlands, Belgium, Korea, Republic of, United Kingdom, Sweden, Denmark, Italy, Japan, Germany, France, Spain, Australia, Israel, Poland, Greece
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

Multiple Myeloma

Canada, United States, Belgium, Korea, Republic of, United Kingdom, Sweden, Italy, Denmark, Japan, Taiwan, China, Germany, Spain, France, Netherlands, Turkey, Russian Federation, Poland, Greece, Argentina, Brazil
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)

Multiple Myeloma

United States, Belgium, Germany, Netherlands, Israel, Spain, Saudi Arabia, France
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myeloid Neoplasm | Myeloid Sarcoma | Leukemia Cutis

United States, Canada, Australia, New Zealand, Puerto Rico
Celgene

Active, not recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Spain, United Kingdom
Ida Bruun Kristensen
Odense Patient Data Explorative Network; Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)

Multiple Myeloma

Denmark, Norway, Estonia
Antengene Corporation

Active, not recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (BENCH)

Relapsed or Refractory Multiple Myeloma

China
University of Michigan Rogel Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Multiple Myeloma

United States
Massachusetts General Hospital
Bristol-Myers Squibb; Celgene; Multiple Myeloma Research Consortium

Active, not recruiting

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb
AbbVie

Active, not recruiting

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Multiple Myeloma

United States, Canada, Australia, Poland, Italy, Belgium, Spain, Japan, Greece, Hungary, Romania, Turkey, United Kingdom
Tianjin Medical University General Hospital

Completed

Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder

China
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Czechia, Canada
University of Arkansas

Active, not recruiting

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Takeda

Active, not recruiting

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Sanofi

Active, not recruiting

Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)

Plasma Cell Myeloma

Mexico, Sweden, Poland, France, Czechia, Greece, Taiwan, Lithuania, Portugal, Spain, Australia, Italy, New Zealand, Russian Federation, Turkey, Japan, United States, Belgium, China, Denmark, Germany
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States, Saudi Arabia, Puerto Rico
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Solid Tumor | Urethral Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China, Taiwan
Janssen Research & Development, LLC

Completed

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Multiple Myeloma

United States, France, Spain
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Adult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditions

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

HIV | Lymphoproliferative Disorder | Malignancy | HHV-8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia | Loss of Chromosome 17p | Autologous Hematopoietic Stem Cell Transplant Recipient

United States
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc.; Celgene Corporation

Active, not recruiting

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Janssen Research & Development, LLC

Completed

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, Poland, Ukraine, Germany, Spain, Turkey, Korea, Republic of, Brazil, Russian Federation, Netherlands, Hungary, Sweden, Czechia, Mexico
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
National Cancer Institute (NCI)

Active, not recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
NYU Langone Health

Completed

High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

GVHD

United States

Search clinical trials for: bortezomib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations